We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

1 hedge funds and large institutions have $34.3K invested in CytoMed Therapeutics in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

35,664% more capital invested

Capital invested by funds: $96 → $34.3K (+$34.2K)

0.09% more ownership

Funds ownership: 0% → 0.09% (+0.09%)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$24.1K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$34.3K +$24.1K +10,037 +16,454%

GDTC Hedge Fund Activity: Q4 2024 in Review

1 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q4 2024, worth a combined $34.3K — up 35,664% from $96 a quarter earlier.

Fund positioning in GDTC was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $24.1K.

  • 1 institutional investor held CytoMed Therapeutics (GDTC) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $34.3K of CytoMed Therapeutics stock for Q4 2024, up 35,664% quarter-over-quarter.
  • 0 funds opened new CytoMed Therapeutics positions in Q4 2024 and 0 closed out.
  • The largest CytoMed Therapeutics buyer in Q4 2024 was UBS Group, an estimated $24.1K added.

Based on aggregated 13F filings for Q4 2024.